The “tissue recovery peptide” class is a colloquial grouping of three frequently co-studied compounds: BPC-157, TB-500, and GHK-Cu. They appear together in much of the published research literature and are often acquired together by labs running comparative studies.
This article describes each compound in research context — its origin, structure, and characterized mechanisms. It does not make claims about clinical effects in humans.
BPC-157 — Body Protection Compound
Structure: a 15-amino-acid synthetic peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a fragment of human gastric protective protein.
Origin: identified in research on gastric mucosa-protective peptides in the 1990s. The “BPC” name derives from “Body Protection Compound” — a label assigned by the original research group based on the fragment’s protective activity in animal model gastric studies.
Characterized mechanisms (from published research):
- Modulation of nitric oxide synthesis in tissue research models
- Effects on growth factor expression in cell culture studies (FGF, VEGF)
- Modulation of dopaminergic and serotonergic systems in animal model neuroscience research
Stability profile: BPC-157 is unusually stable for a small peptide. It survives gastric pH conditions in research models, which is unusual for peptides of its size and is one reason it has been characterized for both injected and oral administration in published studies.
Common research format: 10 mg lyophilized vials. Typical reconstitution at 5 mg/mL with BAC water (2 mL per 10 mg). Matte’s BPC-157 10mg.
TB-500 — Thymosin Beta-4 Fragment
Structure: a 7-amino-acid fragment (sequence: LKKTETQ) derived from the active domain of thymosin beta-4, a 43-amino-acid actin-sequestering protein found in most cell types.
Origin: thymosin beta-4 was first isolated from thymus gland tissue in the 1980s. The “TB-500” name refers specifically to the small synthetic fragment that retains the actin-binding properties of the parent protein but is much shorter and easier to synthesize.
Characterized mechanisms (from published research):
- Actin sequestering — the fragment binds G-actin monomers, modulating cytoskeletal dynamics in cell research
- Cell migration effects — characterized in fibroblast, endothelial, and stem cell migration assays
- Modulation of inflammatory mediators in cell culture studies
The thymosin beta-4 family has been studied extensively in cardiac and dermal research models. TB-500 specifically is the synthetic analog used for many of those studies because it’s more commercially accessible than full-length thymosin beta-4.
Common research format: 10 mg lyophilized vials. Typical reconstitution at 5 mg/mL. Matte’s TB-500 10mg.
GHK-Cu — Copper Tripeptide-1
Structure: a 3-amino-acid peptide (Glycyl-L-Histidyl-L-Lysine) complexed with a copper(II) ion. The copper coordination is central to its biological activity.
Origin: isolated from human plasma in the 1970s. The native form circulates at low concentrations and binds copper with high affinity. The synthetic complex (GHK-Cu) is the form used in most published research.
Characterized mechanisms (from published research):
- Copper transport — the complex delivers copper(II) ions to copper-dependent enzymes
- Effects on collagen and elastin gene expression in fibroblast research
- Modulation of antioxidant enzyme expression in cell culture studies
- Effects on multiple signaling pathways characterized in dermatology and wound research models
Visual identifier: the Cu²⁺ complex gives GHK-Cu a characteristic pale blue color. Lyophilized vials show a faint blue tint to the cake — this is normal and indicates the copper coordination is intact. A white cake (without the blue tint) suggests the copper has dissociated, which is a degradation pathway.
Stability note: GHK-Cu’s copper coordination is sensitive to pH extremes and reducing conditions. Reconstitute with BAC water (neutral pH) and store refrigerated. Avoid co-storage with reducing agents.
Common research format: 100 mg lyophilized vials (the larger size reflects its lower MW per dose in many research protocols). Matte’s GHK-Cu 100mg.
Combination Research
The three compounds are frequently studied together because their characterized mechanisms are non-overlapping. A common research protocol design might co-administer BPC-157 (signaling modulation) and TB-500 (cytoskeletal/migration effects) in the same study, with GHK-Cu (copper-dependent enzyme support) as a third arm.
The BPC-157/TB-500 Blend is supplied co-lyophilized — both compounds in a single vial, tested as a unit on a single COA, simplifying combination research where the dose ratio is fixed.
Larger blends (GLOW Blend: BPC-157 + TB-500 + GHK-Cu; KLOW Blend: KPV + BPC-157 + TB-500 + GHK-Cu) are designed for research protocols that examine combined mechanism studies.
QC Considerations Specific to This Class
- BPC-157 and TB-500 are short peptides (15 and 7 residues respectively), well within the high-purity zone for solid-phase peptide synthesis. ≥99% purity is reliably achievable.
- GHK-Cu requires both peptide-purity QC AND copper-coordination QC. Some COAs report total copper content separately from peptide purity. Matte’s GHK-Cu COA reports both.
- Blends require an additional QC step: confirming the ratio of compounds matches the labeled formulation. Matte’s blend COAs include the percentage of each component as analyzed.
Storage Across the Class
Standard storage rules apply:
- Lyophilized: room-temp stable in transit; refrigerated for medium-term; frozen for long-term
- Reconstituted: refrigerated at 36–46°F, 30–60 day stability with BAC water
- GHK-Cu specifically: avoid pH extremes and reducing agents in any solution
Matte’s reconstitution calculator handles the per-compound math for any vial size and concentration.
The Compliance Note
None of these compounds are approved for human medical use. They are sold strictly as research reagents under the Research Use Only labeling and disclosures that apply to all peptide products at Matte Protocol. The information in this article describes published research and biochemistry, not human clinical effects.
Researchers should consult published peer-reviewed literature for protocol design specific to their study aims.
Research use only. Not for human consumption, veterinary use, or as food additives. Statements have not been evaluated by the US FDA.